Rocket Lab's $2.36 Billion Backlog Masks a Market Demanding Proof, Not Promises

Rocket Lab's record Q2 revenue and $2.36B backlog contrast with a 48% stock drop, as Neutron delays and defense contracts shape investor sentiment.

The gap between what Rocket Lab's order book says and what its share price whispers has rarely been wider. On paper, the company just delivered its strongest quarter ever — revenue up 62 percent year over year, a backlog that has more than doubled in twelve months, and a shrinking quarterly loss. On the trading screen, however, the stock sits roughly 48 percent below the all-time high it touched in May, a disconnect that tells its own story about investor sentiment.

The Numbers Behind the Narrative

Rocket Lab's second-quarter results, released after Monday's US market close, showed revenue of $234.1 million, up from $144.5 million in the prior-year period. The net loss narrowed to $49.3 million from $66.4 million. But the headline figure that has analysts talking is the backlog: $2.36 billion, a 137 percent surge year over year, fueled in part by a third quarter that has already delivered more than $1 billion in new contracts.

The composition of that revenue is shifting in ways that matter. The products division — satellites, spacecraft components, and mission hardware — grew from $92.7 million to $181.3 million, while services revenue came in at $52.7 million. That pivot from pure launch provider to vertically integrated space systems company is the strategic thread running through every major move Rocket Lab has made this year: the acquisition of Motiv Space Systems in May, the planned multibillion-dollar purchase of Iridium Communications, and the unveiling of GHOST, a containerized, relocatable launch system with its first pad in Kodiak, Alaska.

Washington's Wallet Is Wide Open

A parallel tailwind is coming from the US government's expanding space-defense architecture, and Rocket Lab has positioned itself squarely in its path. In early August, the company secured a $397 million contract with the US Space Force for the SB-AMTI program, an orbital-based air-target tracking initiative that will leverage the Neutron rocket. That followed a record $266 million award in late July for up to 18 suborbital missile-defense missions.

The defense pipeline isn't the only thing humming. On August 6, Rocket Lab completed its 92nd Electron mission, delivering another SAR satellite for Japan's iQPS institute into a 575-kilometer orbit. The company has also established Rocket Lab Germany GmbH in Munich, building on its earlier acquisition of Mynaric, to tap into Europe's push for sovereign space capabilities.

Why the Stock Isn't Celebrating

For all the contract momentum, the equity market remains conspicuously unimpressed. The shares trade around €70, nearly half below the 52-week high of €133.80 set in May, and roughly 7 percent beneath the 50-day moving average of €75.42. Over twelve months, however, the stock is still up about 88 percent — a reminder that the recent pullback comes after a substantial run.

The causes of the hesitation are multiple. The delayed first flight of Neutron, now pushed to 2027, has tested investor patience. With an annualized 30-day volatility of 85 percent, this remains a stock that demands strong nerves. The company's guidance for third-quarter GAAP gross margin of 29 to 31 percent — well below the roughly 37.6 percent the market had been expecting — reflects a heavier mix of lower-margin satellite platforms and ongoing investment in Neutron production. Management's explanation is straightforward, but it has nonetheless reset expectations.

Adding to the caution: a trust tied to CEO Peter Beck sold roughly 3.3 million shares in early July under a pre-arranged trading plan, generating around $286.4 million at prices between $81.59 and $101.57. Such sales typically follow a fixed schedule and say little about management's outlook, but they land at an awkward moment when the stock is already under pressure.

The Bull and Bear Case in One Chart

Rocket Lab's balance sheet is the bull case's strongest pillar. The company ended the quarter with $2.13 billion in cash and equivalents, largely built up through $1.53 billion raised from an ongoing equity placement program. That war chest is earmarked for integrating Mynaric and Motiv, funding the Iridium acquisition, and seeing Neutron through its most capital-intensive phase. Institutional confidence is visible too: Cathie Wood's ARK Invest bought roughly 293,000 shares worth about $23.4 million immediately after the results.

The bear case centers on execution risk. Neutron's launch pad is scheduled for delivery in the fourth quarter of 2026, with a first test flight targeted before year-end — a tight window that leaves little room for slippage. Any delay in pad delivery would likely pressure the stock, and the dilution from the equity placement has already exacted a cost on existing shareholders. The shares currently sit just above their 200-day moving average of around €68, a line that has become critical support. A break below could signal a shift in sentiment and open the door toward the year's low of €32.60.

What Comes Next

The market's verdict will hinge on a simple question: can Rocket Lab deliver the Neutron launch pad on schedule without further margin deterioration? If it does, the current patience with heavy cash burn could be rewarded, potentially opening a path back toward the €133.80 high. If third-quarter gross margins fall below the guided 29 to 31 percent range, selling pressure is likely to intensify.

The company's transformation from small-satellite launcher to defense contractor, satellite manufacturer, and soon Iridium's owner is undeniable. Whether investors are willing to pay a premium for that transition — or will wait for Neutron's first successful flight before fully believing the story — is the question that will define the stock's trajectory through the remainder of the year.